Novel therapies for indolent lymphomas in the cellular therapy era PDF Download
Are you looking for read ebook online? Search for your book and save it on your Kindle device, PC, phones or tablets. Download Novel therapies for indolent lymphomas in the cellular therapy era PDF full book. Access full book title Novel therapies for indolent lymphomas in the cellular therapy era by Narendranath Epperla. Download full books in PDF and EPUB format.
Author: Narendranath Epperla
Publisher: Frontiers Media SA
ISBN: 2832538320
Category : Medical
Languages : en
Pages : 126
Get Book Here
Book Description
Author: Narendranath Epperla
Publisher: Frontiers Media SA
ISBN: 2832538320
Category : Medical
Languages : en
Pages : 126
Get Book Here
Book Description
Author: Nicolaus Kröger
Publisher: Springer Nature
ISBN: 3030943534
Category : Medical
Languages : en
Pages : 221
Get Book Here
Book Description
This first open access European CAR-T Handbook, co-promoted by the European Society for Blood and Marrow Transplantation (EBMT) and the European Hematology Association (EHA), covers several aspects of CAR-T cell treatments, including the underlying biology, indications, management of side-effects, access and manufacturing issues. This book, written by leading experts in the field to enhance readers’ knowledge and practice skills, provides an unparalleled overview of the CAR-T cell technology and its application in clinical care, to enhance readers’ knowledge and practice skills.
Author: Tod W. Speer
Publisher: Lippincott Williams & Wilkins
ISBN: 1451153260
Category : Medical
Languages : en
Pages : 564
Get Book Here
Book Description
Radioimmunotherapy, also known as systemic targeted radiation therapy, uses antibodies, antibody fragments, or compounds as carriers to guide radiation to the targets. It is a topic rapidly increasing in importance and success in treatment of cancer patients. This book represents a comprehensive amalgamation of the radiation physics, chemistry, radiobiology, tumor models, and clinical data for targeted radionuclide therapy. It outlines the current challenges and provides a glimpse at future directions. With significant advances in cell biology and molecular engineering, many targeting constructs are now available that will safely deliver these highly cytotoxic radionuclides in a targeted fashion. A companion website includes the full text and an image bank.
Author: Martine Extermann
Publisher: Springer
ISBN: 9783319574141
Category : Medical
Languages : en
Pages : 1150
Get Book Here
Book Description
This book is intended as a comprehensive resource for clinicians and researchers seeking in-depth information on geriatric oncology. The coverage encompasses epidemiology, the biology and (patho)physiology of aging and cancer, geriatric assessment and management, hematologic malignancies, solid tumors, issues in patient care, and research methods. Since cancer is a disease of aging and people are living longer, most cancer patients are now aged 70 and older. Yet the more we age, the more diverse we become in terms of our health, biologic fitness, and cancer behavior. Typically, however, general oncology clinical trials address only a selected healthier and younger population of patients. Geriatric oncology is the area of oncology that addresses these issues but while a wealth of knowledge has been accumulated, information is often difficult to retrieve or insufficiently detailed. The SpringerReference program, in which this book is published, offers an ideal format for overcoming these limitations since it combines thorough coverage with access to living editions constantly updated chapter by chapter via a dynamic peer-review process, ensuring that information remains current and pertinent.
Author:
Publisher:
ISBN:
Category : Cancer
Languages : en
Pages : 194
Get Book Here
Book Description
Author: Marc S. Ernstoff, MD
Publisher: Springer Publishing Company
ISBN: 0826172156
Category : Medical
Languages : en
Pages : 275
Get Book Here
Book Description
The Society for Immunotherapy of Cancer's handbook,SITC’s Guide to Managing Immunotherapy Toxicity, is a practical reference to managing side effects associated with FDA-approved cancer immunotherapy drugs. Separated into two parts, Part I contains chapter-based overviews of immune checkpoint inhibitors in the clinic, starting with anti-CTLA4 agents, anti-PD1/PD-L1 agents, and approved immunotherapeutic combinations. These chapters cover relevant mechanisms of action, indications, and toxicities seen while combating early, advanced, and metastatic stages in cancer patients. Part II is structured by common and uncommon toxicities that affect major organ sites throughout the body. It begins with a general summary of principles and management options followed by chapters focusing on specific toxicities such as rash and mucosal irritation, muscle and joint toxicity, diarrhea and colitis, pneumonitis, endocrine toxicities, neurological toxicities, cardiac toxicity, renal toxicity, hematologic toxicity, and ocular toxicities. Each chapter provides guidance on how to assess and treat the toxicity and how to support the patient through acute and chronic effects with detailed summary tables for quick reference. Part II concludes with chapters covering management of special patient populations, including patients with autoimmune disease and geriatric patients, treatment and management of fatigue, and a final chapter dedicated to cost effectiveness and the toll of financial toxicity on patients and caregivers. With chapters written by world-recognized leaders in the immuno-oncology field, this text provides thorough coverage of the toxicity and management of adverse effects for immune checkpoint inhibitors. It is an indispensable resource for clinical oncologists, emergency physicians, hospitalists and other medical practitioners in both the hospital and community clinic settings, especially as the use of immune checkpoint inhibitors becomes a fixture in oncology care. Key Features: Outlines strategies for treating high-risk patients facing an acute or chronic side effect to immunotherapy Provides numerous tables that condense and highlight pertinent information for quick reference Describes the various clinical presentations and toxic reactions caused by immunotherapy Purchase includes access to the eBook for use on most mobile devices or computer
Author: Elaine Sarkin Jaffe
Publisher: Elsevier Health Sciences
ISBN: 032338871X
Category : Medical
Languages : en
Pages : 1564
Get Book Here
Book Description
The world's leading reference in hematopathology returns with this completely updated second edition. Authored by international experts in the field, it covers a broad range of hematologic disorders -- both benign and malignant -- with information on the pathogenesis, clinical and pathologic diagnosis, and treatment for each. Comprehensive in scope, it's a must-have resource for both residents and practicing pathologists alike. - Authored by the chief architects of the WHO classification in neoplasms of hematopoietic and lymphoid tissue. - Covers the newest diagnostic techniques, including molecular, immunohistochemical, and genetic studies. - Confirm or challenge your diagnostic interpretations by comparing specimens to over 1,000 high-quality color images. - Boasts detailed, practical advice from world leaders in hematopathology. - Places an emphasis on pathologic diagnoses, including molecular and genetic testing. - Updated with the most current WHO classifications of hematologic disease, including lymphoma and leukemia and peripheral T-cell lymphomas. - Covers hot topics in hematopathology, such as the latest genetic insights into lymphoma and leukemia; the new nomenclature for myelodysplastic syndromes; new developments on the subject of Grey zone lymphoma; and much more. - Expert Consult eBook version included with purchase. This enhanced eBook experience allows you to search all of the text, figures, images, and references from the book on a variety of devices. There's also a downloadable image bank, and Virtual Microscope Slides are featured in several chapters.
Author: Klaus Okkenhaug
Publisher: Frontiers Media SA
ISBN: 2889194191
Category : Immunologic diseases. Allergy
Languages : en
Pages : 140
Get Book Here
Book Description
The PI3Ks control many key functions in immune cells. PI3Ks phosphorylate PtdIns(4,5)P2 to yield PtdIns(3,4,5)P3. Initially, PI3K inhibitors such as Wortmannin, LY294002 and Rapamycin were used to establish a central role for Pi3K pathway in immune cells. Considerable progress in understanding the role of this pathway in cells of the immune system has been made in recent years, starting with analysis of various PI3K and Pten knockout mice and subsequently mTOR and Foxo knockout mice. Together, these experiments have revealed how PI3Ks control B cell and T cell development, T helper cell differentiation, regulatory T cell development and function, B cell and T cell trafficking, immunoglobulin class switching and much, much more. The PI3Kd inhibitor idelalisib has recently been approved for the treatment of B cell lymphoma. Clinical trials of other PI3K inhibitors in autoimmune and inflammatory diseases are also in progress. This is an opportune time to consider a Research Topic considering when what we have learned about the PI3K signalling module in lymphocyte biology and how this is making an impact on clinical immunology and haematology.
Author: Howard J. Weinstein
Publisher: Springer Science & Business Media
ISBN: 354068753X
Category : Medical
Languages : en
Pages : 296
Get Book Here
Book Description
This is a comprehensive textbook of Hodgkin's and non-Hodgkin's lymphomas written by leaders in the field of childhood lymphomas. It includes clinical, pathologic and molecular biology of each subtype of lymphoma. The pathology chapters are comprehensive and include excellent photographs. The book is at the level of subspecialists in pediatric hematology and oncology, radiation oncology, pediatric surgery and hematopathology.
Author: Anas Younes
Publisher: Springer Science & Business Media
ISBN: 1627034080
Category : Medical
Languages : en
Pages : 414
Get Book Here
Book Description
Recently, understanding the molecular pathogenesis of malignant lymphomas has led to improvement in the diagnostic precision and to the identification of a variety of molecular therapeutic targets. In addition, new drugs have been approved in the US and Europe, resulting in changes in the standard of care of several types of lymphoid malignancies. Comprehensive in scope and developed by a team of internationally renowned authors, Lymphoma: Diagnosis and Treatment provides a timely update on the most important advances in the biology, diagnosis, and therapy of lymphomas. As part of the Current Clinical Oncology series, Lymphoma: Diagnosis and Treatment will be of value to medical oncologists, hematologists, radiation oncologists, and all physicians involved in the care of patients with lymphoid malignancies.
